Mitsubishi UFJ Asset Management Co. Ltd. Purchases 53,341 Shares of DexCom, Inc. $DXCM

Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,142,726 shares of the medical device company’s stock after acquiring an additional 53,341 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.29% of DexCom worth $76,894,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Marshall Wace LLP grew its stake in shares of DexCom by 260.7% during the 2nd quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock worth $333,630,000 after acquiring an additional 2,762,504 shares in the last quarter. E. Ohman J or Asset Management AB lifted its position in shares of DexCom by 400.2% in the third quarter. E. Ohman J or Asset Management AB now owns 77,492 shares of the medical device company’s stock worth $5,214,000 after purchasing an additional 62,000 shares in the last quarter. Zevenbergen Capital Investments LLC boosted its holdings in DexCom by 10.0% during the third quarter. Zevenbergen Capital Investments LLC now owns 685,433 shares of the medical device company’s stock worth $46,123,000 after purchasing an additional 62,098 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in DexCom by 11.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 212,045 shares of the medical device company’s stock worth $14,269,000 after purchasing an additional 21,352 shares during the last quarter. Finally, Freestone Capital Holdings LLC grew its position in DexCom by 32.1% in the second quarter. Freestone Capital Holdings LLC now owns 29,823 shares of the medical device company’s stock valued at $2,603,000 after purchasing an additional 7,242 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein restated an “outperform” rating and issued a $86.00 price objective (up from $84.00) on shares of DexCom in a report on Friday, January 9th. UBS Group decreased their price target on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. JPMorgan Chase & Co. dropped their price objective on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, October 31st. Evercore initiated coverage on DexCom in a report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price objective for the company. Finally, Argus dropped their price target on shares of DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $85.18.

DexCom Stock Performance

NASDAQ DXCM opened at $73.43 on Friday. The stock has a market cap of $28.26 billion, a PE ratio of 34.97, a P/E/G ratio of 1.45 and a beta of 1.49. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. The firm has a 50-day moving average of $70.24 and a 200-day moving average of $69.23. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.45 EPS. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.